REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 16, 2024 at 03:13 am EDT
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported negative sales was KRW 0.00006 million compared to sales of KRW 0.00006 million a year ago. Net income was KRW 326.17 million compared to KRW 2,007.41 million a year ago.
Basic earnings per share from continuing operations was KRW 18 compared to KRW 112 a year ago. Basic earnings per share was KRW 18 compared to KRW 112 a year ago.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
